skip to Main Content

New Drugs Could Also Be Deployed Against Lung and Pancreatic Cancers

Newsfeed image, light gray text on dark gray background
A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from the Technical University of Munich (TUM) has shown that a new class of drugs known as SHP2 inhibitors is also effective against aggressive, hard-to-treat tumors such as lung and pancreatic cancers. Clinical trials currently underway had previously excluded patients with these cancers.

Lung and pancreatic cancer are collectively referred to as KRAS tumors, as they share the same genetic error. This error means that the KRAS protein, involved in cell division, no longer works properly, and is always active. Read more . . .

Back To Top